Skip to main content
Michael A. Thompson, MD, Oncology, Milwaukee, WI

Michael A.ThompsonMDPhD, FASCO

Oncology Milwaukee, WI

Hematologic Oncology

Vice President of Clinical Partnerships, Tempus Labs

Dr. Thompson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Thompson's full profile

Already have an account?

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2004
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 2001 - 2002
  • Mayo Graduate School (MD/PhD Program)
    Mayo Graduate School (MD/PhD Program)PhD, Molecular Pharmacology & Experimental Therapeutics, 1993 - 2001
  • Mayo Clinic College of Medicine
    Mayo Clinic College of MedicineClass of 2001
  • University of Wisconsin at Madison
    University of Wisconsin at MadisonBS, Molecular Biology, Honors, 1989 - 1993

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 2007 - 2025
  • TX State Medical License
    TX State Medical License 2004 - 2014
  • MN State Medical License
    MN State Medical License 2002 - 2004
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Clinical Trials Research Award Aurora Research Institute, 2014
  • ASCO Leadership Development Program American Society of Clinical Oncology (ASCO), 2012
  • "Man of the Year" Nominee, SE Wisconsin Leukemia & Lymphoma Society (LLS), 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • How can social media improve oncology care?  
    Thompson, MA, Community Oncology, 7/2013
  • Rabbit lung indolethylamine N-methyltransferase three–dimensional structure prediction: a model approach to bridge sequence to function in pharmacogenomic studies.  
    Thompson MA, Weinshilboum RM, El Yazal J, Wood TC, Pang Y-P, J Mol Model.
  • Denileukin diftitox activity in relapsed and refractory B-cell non-Hodgkin's lymphoma.  
    Thompson MA and Dang NH, Am J Oncol Rev
  • Join now to see all

Lectures

  • ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with asses... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Reportable actionability versus pragmatic actionability: Implementing precision medicine at three large health systems. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

  • Indolethylamine N-Methyltransferase (INMT): Structural and Functional Studies 
    Thompson MA
    Mayo Clinic
  • Oncology iPhone Applications: Perspectives From a Researcher/Community-Based Hematologist/Oncologist and a Physician Reviewer of Medical Apps. 
    Thompson MA and Misra S, Oncology. 2012; 26(3):1-2
    http://www.cancernetwork.com/practice/content/article/10165/2044783
  • Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma 
    Li C, Thompson MA, Tamayo AT, Zuo Z, Li C, Lee J, Vega F, Ford RJ, Pham LV, Oncotarget
    http://www.impactjournals.com/oncotarget

Press Mentions

  • Clinical Trial Mythbusters: Does the Clinical Trial Process Need an Extreme Makeover?
    Clinical Trial Mythbusters: Does the Clinical Trial Process Need an Extreme Makeover?July 9th, 2018
  • Session at ASCO Shows Community Oncology Success in Precision Medicine
    Session at ASCO Shows Community Oncology Success in Precision MedicineJune 3rd, 2018
  • What Is the State of Precision Medicine for Myeloma?
    What Is the State of Precision Medicine for Myeloma?March 15th, 2018

Committees

  • CRF Council, ASCO Community Research Forum (CRF) Committee 2013 - Present
  • Member, ECOG-ACRIN Myeloma Core Committee 2009 - Present
  • Co-Chair, VIA Oncology Medical Oncology Lymphoma Committee 2015 - 2021
  • Member, ECOG-ACRIN NCORP Advisory Committee 2014 - 2021
  • Member, ASCO Cancer Education Committee on Lymphoma & Plasma Cell Disorders 2014 - 2017
  • Member, ASCO Cancer Research Committee (CRC) 2013 - 2016
  • Member, Conquer Cancer Foundation (CCF) Annual Giving Development Committee 2013 - 2014
  • Member, ASCO Integrated Media & Technology (IMT) / Education Committee 2010 - 2013